James J Mule
Overview
Explore the profile of James J Mule including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi H, Perez-Villarroel P, Falahat R, Mule J
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40081947
Background: Strategies to improve the therapeutic efficacy of cancer immunotherapy with immune checkpoint inhibitors include targeting additional immunosuppressive compartments in the tumor microenvironment (TME). Inhibitory macrophages (Mφ) can be one...
2.
Berglund A, Puskas J, Yoder S, Smith A, Marchion D, Qin D, et al.
Cancer Res Commun
. 2025 Feb;
5(3):389-397.
PMID: 39932296
The RSI and 12CK GES are two GESs that predict tumor radiation sensitivity or the presence of tertiary lymphoid structures in tumors, respectively. These GESs were assessed within the CLIA...
3.
Kuilman T, Schrikkema D, Gadiot J, Gomez-Eerland R, Bies L, Walker J, et al.
Nat Commun
. 2025 Jan;
16(1):649.
PMID: 39809767
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) can mediate tumor regression, including complete and durable responses, in a range of solid cancers, most notably in melanoma. However, its wider application...
4.
Karapetyan L, Li A, Vargas De Stefano D, Abushukair H, Al-Bzour A, Knight A, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39537211
Background: While the prognostic role of tertiary lymphoid structures (TLS) has been well studied in solid cancers, the prevalence and impact of immature precursor lymphoid structures known as lymphoid aggregates...
5.
Li R, Villa N, Yu X, Johnson J, Borjas G, Dhillon J, et al.
Nat Med
. 2024 Nov;
31(1):176-188.
PMID: 39521884
There is a critical unmet need for safe and efficacious neoadjuvant treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. Here we launched a phase 1b study using the combination of...
6.
Berglund A, Puskas J, Yoder S, Smith A, Marchion D, Qian D, et al.
bioRxiv
. 2024 Sep;
PMID: 39345465
Background: The radiation sensitivity index (RSI) and 12-chemokine gene expression signature (12CK GES) are two gene expression signatures (GES) that were previously developed to predict tumor radiation sensitivity or identify...
7.
Berglund A, Yamoah K, Eschrich S, Falahat R, Mule J, Kim S, et al.
Cancer Med
. 2024 Aug;
13(16):e70044.
PMID: 39162297
Introduction: Men with African ancestry have the highest incidence and mortality rates of prostate cancer (PCa) worldwide. Methods: This study aimed to identify differentially methylated genes between tumor vs. adjacent...
8.
Sarnaik A, Hwu P, Mule J, Pilon-Thomas S
Cancer Cell
. 2024 Jul;
42(8):1315-1318.
PMID: 39029463
Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course...
9.
Hall M, Teer J, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37802604
Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors. While numerous advances have been made, the contribution of neoantigen-specific...
10.
Chakiryan N, Kim Y, Berglund A, Chang A, Kimmel G, Hajiran A, et al.
J Immunother Cancer
. 2023 May;
11(4).
PMID: 37185232
Introduction: In clear cell renal cell carcinoma (ccRCC), tumor-associated macrophage (TAM) induction of CD8+T cells into a terminally exhausted state has been implicated as a major mechanism of immunotherapy resistance,...